2018 Press Releases

Webcast ImageWebcast
MyoKardia Inc at the at the RBC Capital Markets 2018 Healthcare Conference (Replay)
February 21, 2018 at 8:30 a.m. ET
MyoKardia Inc at the at the RBC Capital Markets 2018 Healthcare Conference
Wednesday, February 21, 2018 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
02/14/18MyoKardia to Present at the RBC Capital Markets’ 2018 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that senior management will participate in a fireside chat at the RBC Capital Markets’ 2018 Healthcare Conference on Wednesday, February 21, 2018, at 8:30 a.m. ET in New York, NY.   A webcast of the presentation will be available by visiting the... 
02/14/18MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients
Topline Results from First-in-Human Phase 1 Study of MYK-491 in Healthy Volunteers Demonstrated Tolerability and Increased Contractility SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that dosing has commenced in a Phase 1b single-ascending dose patient study of its investigational drug candid... 
01/19/18MyoKardia Announces Appointment of Cynthia Ladd as General Counsel
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the expansion of its executive committee with the appointment of Cynthia Ladd as General Counsel. “Cynthia brings substantial experience as a biotech executive and expertise in intellectual property, business development, corporate governance an... 
01/03/18MyoKardia to Present at 36th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th, 2018, at 2:30 p.m. PT (5:30 p.m. ET) in San Francisco. A webcast of the presentation will be a...